Rick Martin presented “Next Generation Sequencing + PCR: The Key to Clearing Chronic Urological Infections” during the 30th Annual International Prostate Cancer Update on January 23rd, 2020 in Beaver Creek, Colorado.
How to cite: Martin, Rick. “Next Generation Sequencing + PCR: The Key to Clearing Chronic Urological Infections” January 23rd, 2020. Accessed Nov 2024. https://dev.grandroundsinurology.com/next-generation-sequencing-pcr-the-key-to-clearing-chronic-urological-infections/
Next Generation Sequencing + PCR: The Key to Clearing Chronic Urological Infections – Summary:
Rick Martin, CEO of MicroGen DX, discusses how his company is working to better detect microbes. He outlines their use of Next Generation Sequencing (NGS) which is faster, cheaper, more accurate, and allows the casting of a broader net in identifying microbe species than previously used tests. Patients with rare and hard to treat UTI infections particularly benefit from this type of testing. This is because bacteria adaption can result in culture ID evasion making these types of tests ineffective, but NGS tests DNA so this issue is not a problem. Martin emphasizes that the real strength of NGS is its database of sequence codes, which to date had more than 50,000 more than any other company or academic center.
About The 30th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. Mr. Martin delivered this educational activity during the 30th iteration of the meeting in January 2020.
For further educational activities from this conference, visit our collection page.
ABOUT THE AUTHOR
Rick Martin is the CEO of MicroGen Diagnostics in Orlando, Florida. MicroGen Diagnostics specializes in next-generation DNA sequencing for the diagnosis of microbial infections, and their MicroGenDX® system of molecular diagnostics reduces the likelihood of errors in specimen collection, handling, stability, and time to analysis. Mr. Martin received his undergraduate degree from the University of Massachusetts Amherst. He then went on to work in sales and marketing for Pfizer for eight years. He has been with MicroGen Diagnostics since 2016.